adriblastina
laboratÓrios pfizer ltda - antibioticos antineoplasicos
cloridrato de doxorrubicina
eurofarma laboratÓrios s.a. - cloridrato de doxorrubicina - antibioticos antineoplasicos
evorubicin
farmarin industria e comercio ltda - cloridrato de doxorrubicina - antibioticos antineoplasicos
evorubicin
evolabis produtos farmacÊuticos ltda - antibioticos antineoplasicos
evorubicin
hospira produtos hospitalares ltda - antibioticos antineoplasicos
oncodox
ucb biopharma ltda. - antineoplasico
polivy
roche registration gmbh - polatuzumab vedotin - linfoma de células b - agentes antineoplásicos - polivy em combinação com bendamustine e o rituximab é indicado para o tratamento de pacientes adultos com recidivado/refratário difuso de grandes células b linfoma (dlbcl), que não são candidatos a transplante de células tronco hematopoiéticas. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - outros agentes antineoplásicos - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
zoltec
pfizer brasil ltda - fluconazol - antimicoticos sistemicos
zoltec
laboratÓrios pfizer ltda - antimicoticos sistemicos